Luis Raez: Clinical and Economic Impact of Delays in Approving Innovative Lung Cancer Therapies
Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post on X:
“This paper shows that substantial clinical and economic impact of delays in approving innovative therapies, underscoring the potential of improving regulatory processes to increase the availability of lung cancer treatments. Congrats to Andres F. Cardona, Oscar Arrieta for leading this effort and thanks for inviting us to participate.”
Title: Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study
Authors: Andrés F. Cardona, Natalia Sánchez, Liliana Gutiérrez-Babativa, Leonardo Rojas, Jairo Zuluaga, Stella Martínez, Lucia Viola, Carlos Carvajal, Juliana Bogoya, Laura Prieto-Pinto, Daniel Samacá-Samacá, Antonio Robles, Joshua Kocke, Claudio Martín, Luis Corrales, Luis E. Raez, Vladmir Cordeiro de Lima, Suraj Samtani, Oscar Arrieta
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023